Drug Trial Radar · NCT05388669
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
418
Actual
Start
Aug 5, 2022
Primary completion
Jan 3, 2024
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- May 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
LazertinibDrug
Lazertinib tablets will be administered orally.
Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)Drug
Amivantamab injection will be administered subcutaneously by manual injection.
Amivantamab IntravenousDrug
Amivantamab will be administered by IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady StateTime frame: Pre-dose on Cycle 4 Day 1 (each cycle of 28 days)
- For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of AmivantamabTime frame: Pre-dose on Cycle 2 Day 1 (each cycle of 28 days)
- Area Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2Time frame: Cycle 2: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hours (hrs) post-dose on Day 1; Arm B: pre-infusion, end of infusion (EOI)+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1
Locations
187 sites in 20 countries. Site status is shown where the registry gives one.
City of Hope Duarte
Duarte, California
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California
City of Hope Long Beach Elm
Long Beach, California
National Jewish Health
Denver, Colorado
Baptist Lynn Cancer Institute
Boca Raton, Florida
Orlando Health
Orlando, Florida
University of Kansas
Kansas City, Kansas
University of Michigan
Ann Arbor, Michigan
Astera Cancer Care
East Brunswick, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
NYU Langone Health Laura and Isaac Perlmutter Cancer Center
New York, New York
Montefiore Medical Center
The Bronx, New York
Providence Portland Medical Center
Portland, Oregon
Providence Oncology and Hematology Care Clinic Westside
Portland, Oregon
University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Virginia Cancer Specialists
Fairfax, Virginia
CEMIC (Centro de Educación Médica e Investigaciones Clínicas)
Buenos Aires, Argentina
IADT Instituto Argentino de Diagnostico y Tratamiento
CABA, Argentina
Centro Oncológico Korben
Chabas, Argentina
Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
Córdoba, Argentina
Sanatorio Allende
Córdoba, Argentina
Clínica Viedma
Viedma, Argentina
Cancer Research SA
Adelaide, Australia
Chris O'Brien Lifehouse
Camperdown, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
St John of God Hospital Murdoch
Murdoch, Australia
Westmead Hospital
Westmead, Australia
Princess Alexandra Hospital
Woolloongabba, Australia
Fundacao Pio XII
Barretos, Brazil
Cetus Oncologia
Belo Horizonte, Brazil
Instituto Cionc de Ensino e Pesquisa S/S
Curitiba, Brazil
Ynova Pesquisa Clinica
Florianópolis, Brazil
Fundacao Sao Francisco Xavier HMC Unidade de Oncologia
Ipatinga, Brazil
UPCO Unidade de Pesquisa Clinica em Oncologia
Pelotas, Brazil
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
Porto Alegre, Brazil
Impar Servicos Hospitalares S/A
Rio de Janeiro, Brazil
Oncoclinicas Rio de Janeiro S A
Rio de Janeiro, Brazil
Instituto D Or de Pesquisa e Ensino IDOR
Rio de Janeiro, Brazil
Nucleo de Oncologia da Bahia
Salvador, Brazil
Showing 40 of 187 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.